145 related articles for article (PubMed ID: 36429732)
1. Sulfonylurea Use in Patients with Type 2 Diabetes and COPD: A Nationwide Population-Based Cohort Study.
Yen FS; Wei JC; Yu TS; Hsu CY; Hsu CC; Hwu CM
Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36429732
[TBL] [Abstract][Full Text] [Related]
2. Respiratory Outcomes of Insulin Use in Patients with COPD: A Nationwide Population-Based Cohort Study.
Yen FS; Chang SH; Wei JC; Shih YH; Hwu CM
Pharmaceuticals (Basel); 2023 Apr; 16(5):. PubMed ID: 37242426
[TBL] [Abstract][Full Text] [Related]
3. Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis.
Yen FS; Lai JN; Wei JC; Chiu LT; Hwu CM; Hou MC; Hsu CC
PLoS One; 2020; 15(12):e0243783. PubMed ID: 33315940
[TBL] [Abstract][Full Text] [Related]
4. Respiratory outcomes of metformin use in patients with type 2 diabetes and chronic obstructive pulmonary disease.
Yen FS; Wei JC; Yang YC; Hsu CC; Hwu CM
Sci Rep; 2020 Jun; 10(1):10298. PubMed ID: 32581289
[TBL] [Abstract][Full Text] [Related]
5. Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: A matched-subject design.
Yen FS; Chen W; Wei JC; Hsu CC; Hwu CM
PLoS One; 2018; 13(10):e0204859. PubMed ID: 30286138
[TBL] [Abstract][Full Text] [Related]
6. Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes.
Yen FS; Hou MC; Wei JC; Shih YH; Hwu CM; Hsu CC
BMC Med; 2024 Jan; 22(1):8. PubMed ID: 38172833
[TBL] [Abstract][Full Text] [Related]
7. Metformin use and the risk of bacterial pneumonia in patients with type 2 diabetes.
Yen FS; Wei JC; Shih YH; Hsu CC; Hwu CM
Sci Rep; 2022 Feb; 12(1):3270. PubMed ID: 35228620
[TBL] [Abstract][Full Text] [Related]
8. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Yang CT; Yang CY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
[TBL] [Abstract][Full Text] [Related]
9. Thiazolidinedione Use in Individuals With Type 2 Diabetes and Chronic Obstructive Pulmonary Disease.
Yen FS; Wei JC; Yang YC; Hsu CC; Hwu CM
Front Med (Lausanne); 2021; 8():729518. PubMed ID: 34957135
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes.
Yen FS; Wei JC; Hung YT; Hsu CY; Hwu CM; Hsu CC
Front Microbiol; 2023; 14():1118000. PubMed ID: 36876083
[TBL] [Abstract][Full Text] [Related]
11. Metformin Use before Influenza Vaccination May Lower the Risks of Influenza and Related Complications.
Yen FS; Wei JC; Shih YH; Hsu CY; Hsu CC; Hwu CM
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298617
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study.
Tseng CH
Int J Chron Obstruct Pulmon Dis; 2022; 17():285-295. PubMed ID: 35177899
[TBL] [Abstract][Full Text] [Related]
13. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
Cho YY; Cho SI
Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
Anyanwagu U; Mamza J; Mehta R; Donnelly R; Idris I
Heart; 2016 Oct; 102(19):1581-7. PubMed ID: 27217068
[TBL] [Abstract][Full Text] [Related]
15. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
16. Metformin and risk of chronic obstructive pulmonary disease in diabetes patients.
Tseng CH
Diabetes Metab; 2019 Apr; 45(2):184-190. PubMed ID: 29804817
[TBL] [Abstract][Full Text] [Related]
17. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.
Yen FS; Huang YH; Hou MC; Hwu CM; Lo YR; Shin SJ; Hsu CC
Br J Clin Pharmacol; 2022 Jan; 88(1):311-322. PubMed ID: 34198358
[TBL] [Abstract][Full Text] [Related]
18. Metformin and the Risk of Chronic Urticaria in Patients with Type 2 Diabetes.
Yen FS; Hsu CC; Hu KC; Hung YT; Hsu CY; Wei JC; Hwu CM
Int J Environ Res Public Health; 2022 Sep; 19(17):. PubMed ID: 36078769
[TBL] [Abstract][Full Text] [Related]
19. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
